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of allo HSCT. Recently it has been shown that a hap-
loidentical donor could be a valid option to perform allo
HSCT given adapted immunosuppression is used. Notably
the use of PT-HDCy, after T-replete HSCT following reduced
intensity (RIC) or non-myeloablative (NMAC) conditioning,
has been associated with promising results. However little
data exist concerning elderly population when this popu-
lation is characterized by a lack of HLA matched sibling and
a higher incidence of severe GVHD and non-relapse
mortality.
Using this strategy we transplanted 31 patients over the age
of 55 years between 2010 and 2014 and compare their
outcome with patients of the same age transplanted in the
same period from a MRD or UD.
70% of the patients in haplo group were prepared with
Flu-TBI 2gy (NMAC) (30% received Fludarabine-Busilvex
based regimen without ATG) while all patients in other
groups received the same RIC (Fludarabine (150 mg/m2)
Busilvex (2 days) rabbit ATG (2 days)). Patients in haplo
group received post graft immunosuppression with PT-
HDCy (50 mg/kg on D 3 and 4) followed with CSA and
MMF while patients in other groups received either CSA
starting on D1.
Patients in the haplo group have a trend presenting
higher comorbidities and more severe diseases (Table). A
single graft failure related to donor anti-HLA antibodies
were noted in haplo group. Median time to 0.5x109 ANC
and 20x109platelets were respectively 21 (14-32) and 28
(14-52) days after haplo HSCT. Haplo and MRD HSCT
patients presented with a similar NRM lower than UD
patients while Haplo patients present a relapse rate in-
termediate between MRD and UD (table). Overall
outcome after haplo do not differ from MRD transplant.
There is a trend for better PFS after Haplo HSCT as
compared with UD transplant (62% vs.41%; P¼0,14)
(Figure 1). Progression-free and severe cGVHD-free sur-
vival was signiﬁcantly better after haplo HSCT (62% vs.
35%; p¼0.03) (Figure 2).
We conclude that T-replete Haplo HSCT after RIC and fol-
lowed by PT-HDCy is associated with promising results
notably as compared with UD HSCT. The low rate of severe
aGVHD and cGVHD are likely to conduct to lower compli-
cations and better quality of life. The reduction of donor
search duration and the absence of graft acquisition fees
represent potential additional beneﬁts. In this perspective,
the place of Haplo HSCT in older patients should now be
prospectively addressed.388
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ZAP70 (zeta-associated protein of 70 KDa) deﬁciency is a
fatal form of combined immunodeﬁciency that can be cured
with hematopoietic stem cell transplantation (HSCT). The
normal number of thymocytes, polyclonal CD3⁺ T cells and B
cells may require special considerations in choosing themost
effective regimen of conditioning and the type of HSCT. We
analyzed presentation and outcome of patients with ZAP70
deﬁciency who received various modalities of stem cell
transplantation.
Data on 19 patients with ZAP70 deﬁciency were exam-
ined, of whom 16 underwent HSCT in 7 different
counties. HSCT was performed by using different sources
of donor stem cells as well as various conditioning
regimens.
Most patients presented with typical repeated microbial
and fungal infections; one patient presented with lym-
phoma. Close family members appear to have a high fre-
quency of autoimmunity. Sixteen of nineteen patients
were treated with HSCT. Nine patients received a MRD
and 8/9 survived, four patients had MUD transplants and
all survived and 3 had a MMRD transplant of which only
one survived. Immune reconstitution was complete and
durable in patients who received myeloablative condi-
tioning. Lack of conditioning failed in two patients and
resulted in partial immune reconstitution in the other
patients.
Based on these data, we conclude that carriers of monoallelic
mutations in ZAP70 may be susceptible to autoimmunity.
HLAmatched donor andmyeloablative conditioning result in
superior outcome and long-term robust immune re-
constitution.389
AMulticenter Phase I/II Study of Relapse Prophylaxis with
Nilotinib after Hematopoietic Cell Transplantation (HCT)
for High-Risk Philadelphia Chromosome-Positive (Ph+)
Leukemias
Paul A. Carpenter 1, Laura Johnston 2, Hugo Fernandez 3,
Jerald Radich 4, Michael J. Mauro 5, Mary E.D. Flowers 1,
Paul J. Martin 1, Ted Gooley 6. 1 Clinical Research Division, Fred
Hutchinson Cancer Research Center, Seattle, WA; 2Division of
Blood and Marrow Transplantation, Stanford University
Medical Center, Stanford, CA; 3 Blood and Marrow
Transplantation, H. Lee Mofﬁtt Cancer Center and Research
Institute, Tampa, FL; 4 Clinical Research Division, Fred
Hutchinson Cancer Research Center, Seattle, WA; 5Hematology,
Oregon Health Sciences University, Portland, OR; 6 Division of
Clinical Research, Fred Hutchinson Cancer Research Center,
Seattle, WA
Background: In a previous study, we showed that relapse
prophylaxis with imatinib (IM) is feasible early after alloge-
neic HCT for treatment of Ph+ leukemia [Carpenter et al,
Blood 2007;109:2791]. The goal of the current study was to
ask whether nilotinib (NIL) might address IM resistance (IR)
or intolerance (IT) because IR leukemia might be sensitive to
NIL. Previous non-HCT trials have shown that NIL and IM
have comparable hematopoietic toxicity, but the incidence of
edema and gastrointestinal toxicity is less with NIL thanwith
IM.
Figure.
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high-risk Ph+ leukemia were enrolled. Given NIL’s unique
QTc prolongation risks and data showing that IM can be
given early after engraftment, IM was given for the ﬁrst
80 days after HCT. Treatment was then changed to NIL
prophylaxis at day 81. Based on risk-beneﬁt consider-
ations IR cases and IT patients began NIL before day 80
but at lower dose. The primary safety endpoint deﬁned
“success” as administration of NIL at 400 mg/day for
85% of time from days 81-365, but 1 full year of NIL
therapy was planned through day 445. The primary efﬁ-
cacy endpoint deﬁned “success” as molecular remission
(CMR) at 1 yr.
Results: See Figure. 1) 28/57 of patients registered in the
study did not begin or continue NIL because of post-HCT
eligibility exclusions: most frequently QTc>450 (n¼7) or
myocardial infarction (n¼2), early relapse (n¼8), and otherexclusions because of laboratory abnormalities (n¼6). 2)
We conﬁrmed our prior data that IM is tolerable early
post-HCT: 28/29 tolerated treatment at a median of 100%
of the intended dose (range, 48%-100%) for a median of 42
days. 3) 9/11 IR/IT cases tolerated NIL early post-HCT (data
not shown). 4) 13/57 patients registered in the study or
13/40 (32.5%) who maintained eligibility at engraftment,
tolerated NIL between days 81 and 365. Another 11/40
received NIL at a median intended dose intensity of 99%
for a median of 130 days before stopping prematurely
because of relapse or reasons other than toxicity. 5) 19/40
subjects had 38 possibly (33), probably (4) or deﬁnitely
related, grade 3/4 non-serious AEs: cytopenias (84%) and
metabolic abnormalities (16%). 6) 38/40 were not in
complete molecular remission (CMR) pre-HCT. 28/40 (70%:
23 ALL, 4 advanced CML) are alive at a median 4.4 yrs
(range 1-5.7), with 26 in CMR. The 2 patients without
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321S276CMR either did not start NIL or stopped at day 110. 4/40
subjects died with progressive leukemia (1 isolated CNS
relapse) and 8/40 died with non-relapse causes.
Conclusions: Efﬁcacy data are encouraging, but the
post-HCT relapse prophylaxis approach with NIL is
limited by QTc prolongation (16% of all registered pa-
tients), early relapse before prophylaxis can begin, and
by miscellaneous post-HCT events that preclude NIL
administration.390
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Introduction: Daily blood cultures during febrile illness are
standard of care in many centers for post allogeneic he-
matopoietic cell transplant patients (alloHCT). The clinical
signiﬁcance of obtaining daily blood cultures for febrile
illness has not been examined to our knowledge in the
literature. Daily blood cultures are associated with iatro-
genic blood loss and central line access. We report the
incidence rate of bloodstream bacterial infections (BBSI)
after four consecutive negative blood cultures between
2000-2013. Other testing modalities for occult infection
including CT scan, viral PCR, and fungal cultures were also
examined.
Methods: A retrospective chart review between 2000-
2013 was conducted. Included were alloHCT patients
with febrile illness (deﬁned as greater than four negative
consecutive blood cultures). The descriptive statistics was
calculated and Fisher’s exact test was used for compar-
ison among rates.
Results: Between 2000-2013, 158 cases in 83 patients
were identiﬁed who met our criteria (mean age 10.6
years). Indication for alloHCT: malignant 62 (74.7%), non-
malignant 21 (25.3%); conditioning regimen:
myeloablative¼ 52 (62.7%) reduced toxicity¼ 10 (12.1%),
reduced intensity¼ 21 (25.3%). Incidence of neutrophil
engraftment by day +30 was 67.5%, and incidence of
aGVHD was 54.2%.
Of those patients with febrile illness, 12% had BBSIs after 4
consecutive negative cultures. Mean time to developing BBSI
was 10.6 (+/- 4.19) days. The most common BBSI was gram
positive cocci (GPC) [89%]. Of these infections, 28% grew
Staphylococcus epidermidis. Gram negative rods (GNR) only
compromised 11% of BBSIs found. A signiﬁcant risk factor for
BBSI was length of febrile illness greater than 7 days
(p¼0.016).
The most obtained modality for identifying other sources
of infection were CT scans and viral studies (both culture
and PCR) [61.2% and 61.4%, respectively]. The rate of positive
results for these tests was 29.1% and 10.9%, respectively.
Other tests utilized to ﬁnd occult infection included fungal
cultures (36.1%) and bronchoalveolar lavage (BAL) (15.3%).
The rate of positivity for these tests was 0.63% and 4.4%
respectively.Discussion: Twelve percent of patients developed BBSI
after 4 sequential days of negative blood cultures, the
majority occurring >7 days of febrile illness. Of those in-
fections, the majority were GPCs possible secondary to
indwelling catheters colonization. Probability of ﬁnding a
true BBSI after 4 negative blood cultures is very low. Of
the different modalities used to search for occult infection,
CT scans have the highest yield in comparison to viral,
fungal or BAL studies, suggesting that obtaining CT scans
earlier in fever may be beneﬁcial. Utility of obtaining daily
blood cultures in febrile alloHCT patients should be pro-
spectively studied.391
Minor ABO Incompatibility Does Not Impact Non-Relapse
Mortality in T-Cell Depleted HLA-Matched Sibling
Transplantation
Puja D. Chokshi, Prathima Anandi, Natasha A. Jain,
Neil Dunavin, Robert Q. Le, Sawa Ito, A. John Barrett,
Minoo Battiwalla. Hematology Branch, National Heart, Lung,
and Blood Institute, NIH, Bethesda, MD
Introduction: ABO incompatibility (ABO-I) in allogeneic
stem cell transplantation is known to produce hemolytic
complications including acute hemolysis, the passenger
lymphocyte syndrome, delayed transfusion dependence and
pure red cell aplasia. Hemolysis is a consequence of ABO
expression on red blood cells (RBCs) and the natural occur-
rence of isohemagglutinins. However, ABO antigens are also
expressed on tissues other than RBCs such as endothelial
cells. It is plausible that donor vs recipient (Minor) ABO-I
may adversely impact organ function and survival after
transplantation. Indeed, in contrast to historic data, one
report found that ABO-I increased non-relapse mortality
(NRM) in reduced intensity transplantation (Resnick et al.,
BBMT 2008). We conducted a large retrospective study to
evaluate the hypothesis that Minor ABO-I impacts overall
survival (OS) and NRM in allogeneic stem cell
transplantation.
Patients and Methods: We analyzed 374 patients who had
undergone allogeneic transplants for hematologic malig-
nancies from HLA-matched sibling donors between the
years 1993e2014. 71 patients had either Minor (including
bidirectional) ABO-I, 55 patients had Major (recipient vs
donor) ABO-I, and 248 patients had no ABO-I. The median
age at transplantation was 38 years. 162 (43%) had AML/
MDS, 120 (32%) had CML/CMMoL, 63 (17%) had ALL, 18 (5%)
had NHL/CLL and 14 (4%) had other diagnoses. 344 (92%)
received a Cytoxan/TBI-based myeloablative conditioning
and 30 (8%) received reduced intensity conditioning. The
graft source was either peripheral blood stem cells in 336
(90%) or bone marrow in 38 (10%) and was ex vivo T cell
depleted in 99%. There were no signiﬁcant differences be-
tween Minor ABO-I and other groups with respect to
baseline variables. Kaplan-Meier estimates were used to
determine OS, NRM and cumulative incidence of relapse,
with differences between groups determined by the log-
rank test.
Results: At a median follow up duration of 11 years, the OS
for Minor/bi ABO-I was 43% vs 40% for others (p¼0.8). NRM
was 38% for Minor/bi ABO-I vs 42% for others (p¼0.6). The
cumulative incidence of relapse was 58% for Minor/bi ABO-I
vs 50% for others (p¼0.1). Findings were similar when ABO-I
status was categorized into three groups (Major, Minor/bi vs
